Table 2.
Characteristics of the included trials and participants.
| Included trials | Treatment group | Control group | ||||||
|---|---|---|---|---|---|---|---|---|
| Treatment durations (weeks*) | Adverse drug reactions | Age (yr) | NO. (M/F) | Intervention | Age (yr) | NO. (M/F) | Intervention | |
| Huang, 2013[51] | 12 | NO | 45.3 ± 6.8 | 16 (2/14) | Thyroxine + Calcitriol 0.25µg, qd, p.o | 43.7 ± 8.6 | 16 (3/13) | Thyroxine |
| Han et al, 2015[50] | 24 | NR† | 34.8 ± 8.2 | 32 (5/27) | Thyroxine + Calcitriol 0.25µg, qd, p.o | 35.2 ± 7.1 | 30 (4/26) | Thyroxine |
| Zhao et al, 2016[48] | 24 | NO | 42 ± 7 | 18 (5/13) | Thyroxine + Calcitriol 0.25µg, qd, p.o | 41 ± 5 | 18 (4/14) | Thyroxine |
| Parichehr Vahabi Anaraki et al, 2017[36] | 12 | NO | 43.55 ± 8.54 | 30 (9/21) | Thyroxine + Vitamin D3 50000IU, qw, p.o | 44.12 ± 8.54 | 26 (11/15) | Thyroxine + Placebo |
| Zhou et al, 2018[49] | 12 | NR | 20–70 | 61 (NR) | Vitamin D2 7.5mg, qm, i.m | 20–70 | 61 (NR) | NO |
| Zuo et al, 2018[45] | 24 | NO | 44.3 ± 2.1 | 35 (6/29) | Calcitriol 0. 25µg, qd, p.o | 42.8 ± 2.0 | 35 (5/30) | NO |
| Fu et al, 2019[34] | 12 | NO | 49.56 ± 7.88 | 36 (2/34) | Calcitriol 0. 25µg, qd, p.o | 47.11 ± 11.42 | 34 (2/32) | NO |
| Reza Chahardoli et al, 2019[31] | 12 | NO | 36.4 ± 5.2 | 19 (0/19) | Thyroxine + Calcitriol 50000IU, qw, p.o | 35.9 ± 7.8 | 21 (0/21) | Thyroxine + Placebo |
| Jia, 2020[47] | 16 | Nausea, vomiting, and rash‡ | 41.96 ± 9.28 | 51 (22/29) | Thyroxine + Calcitriol 0.25µg, qd, p.o | 42.20 ± 8.98 | 51 (20/31) | Thyroxine |
| Xiao et al, 2020[44] | 12 | NR | 45.02 ± 7.11 | 40 (13/27) | Vitamin D2 7.5mg, qm, i.m | 46.38 ± 7.69 | 40 (11/29) | NO |
| Zhang, 2020[46] | 24 | NO | 35.2 ± 7.6 | 45 (20/25) | Thyroxine + Calcitriol 0.25µg,qd, p.o | 34.4 ± 6.3 | 45 (16/29) | Thyroxine |
| Zhao, 2022[33] | 13–15 | NR | 36.55 ± 10.21 | 46 (NR) | Vitamin D3 800-2000§ IU, qd, p.o | 36.55 ± 9.72 | 46 (NR) | NO |
*
1 month = 4 weeks.
†
Not reported.
‡
In treatment group, there were 2 cases of nausea, 2 cases of vomiting, and 1 case of rash; in the control group, there were 2 cases of nausea, 1 case of vomiting, and 0 cases of rash. However, there was no significant difference in the incidence of adverse reactions between the treatment group and the control group.
§
Supplement vitamin D3 at 2000 IU/day when 25(OH)D was < 20 ng/mL, and at 800–1000 IU/d when 20 ng/mL ≤ 25(OH)D < 30 ng/mL.